758 related articles for article (PubMed ID: 24237632)
1. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy.
Porter BE; Jacobson C
Epilepsy Behav; 2013 Dec; 29(3):574-7. PubMed ID: 24237632
[TBL] [Abstract][Full Text] [Related]
2. Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome.
Hussain SA; Zhou R; Jacobson C; Weng J; Cheng E; Lay J; Hung P; Lerner JT; Sankar R
Epilepsy Behav; 2015 Jun; 47():138-41. PubMed ID: 25935511
[TBL] [Abstract][Full Text] [Related]
3. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.
Devinsky O; Marsh E; Friedman D; Thiele E; Laux L; Sullivan J; Miller I; Flamini R; Wilfong A; Filloux F; Wong M; Tilton N; Bruno P; Bluvstein J; Hedlund J; Kamens R; Maclean J; Nangia S; Singhal NS; Wilson CA; Patel A; Cilio MR
Lancet Neurol; 2016 Mar; 15(3):270-8. PubMed ID: 26724101
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Safety, Tolerability, and Efficacy of Cannabidiol in Children with Refractory Epilepsy: Results from an Expanded Access Program in the US.
Sands TT; Rahdari S; Oldham MS; Caminha Nunes E; Tilton N; Cilio MR
CNS Drugs; 2019 Jan; 33(1):47-60. PubMed ID: 30460546
[TBL] [Abstract][Full Text] [Related]
5. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results.
Laux LC; Bebin EM; Checketts D; Chez M; Flamini R; Marsh ED; Miller I; Nichol K; Park Y; Segal E; Seltzer L; Szaflarski JP; Thiele EA; Weinstock A;
Epilepsy Res; 2019 Aug; 154():13-20. PubMed ID: 31022635
[TBL] [Abstract][Full Text] [Related]
6. Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy.
Press CA; Knupp KG; Chapman KE
Epilepsy Behav; 2015 Apr; 45():49-52. PubMed ID: 25845492
[TBL] [Abstract][Full Text] [Related]
7. Cannabis for the Treatment of Epilepsy: an Update.
Gaston TE; Szaflarski JP
Curr Neurol Neurosci Rep; 2018 Sep; 18(11):73. PubMed ID: 30194563
[TBL] [Abstract][Full Text] [Related]
8. Cannabidiol as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.
Lattanzi S; Trinka E; Russo E; Striano P; Citraro R; Silvestrini M; Brigo F
Drugs Today (Barc); 2019 Mar; 55(3):177-196. PubMed ID: 30938373
[TBL] [Abstract][Full Text] [Related]
9. Cannabidiol Therapy for Refractory Epilepsy and Seizure Disorders.
Golub V; Reddy DS
Adv Exp Med Biol; 2021; 1264():93-110. PubMed ID: 33332006
[TBL] [Abstract][Full Text] [Related]
10. Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome.
Lattanzi S; Trinka E; Striano P; Rocchi C; Salvemini S; Silvestrini M; Brigo F
CNS Drugs; 2021 Mar; 35(3):265-281. PubMed ID: 33754312
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy and safety of cannabidiol (CBD) in children with treatment-resistant epilepsy: Results from a state-based expanded access program.
Park YD; Linder DF; Pope J; Flamini JR; Moretz K; Diamond MP; Long SA
Epilepsy Behav; 2020 Nov; 112():107474. PubMed ID: 33181893
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic and clinical foundations of cannabidiol therapy for difficult-to-treat seizures in children and adults with refractory epilepsies.
Reddy DS
Exp Neurol; 2023 Jan; 359():114237. PubMed ID: 36206806
[TBL] [Abstract][Full Text] [Related]
13. Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy.
Perry MS
Epilepsy Curr; 2019; 19(2):93-95. PubMed ID: 30955420
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: Practical experiences in a tertiary medical center.
Porcari GS; Fu C; Doll ED; Carter EG; Carson RP
Epilepsy Behav; 2018 Mar; 80():240-246. PubMed ID: 29429908
[TBL] [Abstract][Full Text] [Related]
15. Purified Cannabidiol for Treatment of Refractory Epilepsies in Pediatric Patients with Developmental and Epileptic Encephalopathy.
Pietrafusa N; Ferretti A; Trivisano M; de Palma L; Calabrese C; Carfì Pavia G; Tondo I; Cappelletti S; Vigevano F; Specchio N
Paediatr Drugs; 2019 Aug; 21(4):283-290. PubMed ID: 31179531
[TBL] [Abstract][Full Text] [Related]
16. The Long-Term Effectiveness and Safety of Cannabidiol-Enriched Oil in Children With Drug-Resistant Epilepsy.
Tzadok M; Hamed N; Heimer G; Zohar-Dayan E; Rabinowicz S; Ben Zeev B
Pediatr Neurol; 2022 Nov; 136():15-19. PubMed ID: 36049378
[TBL] [Abstract][Full Text] [Related]
17. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.
Devinsky O; Cilio MR; Cross H; Fernandez-Ruiz J; French J; Hill C; Katz R; Di Marzo V; Jutras-Aswad D; Notcutt WG; Martinez-Orgado J; Robson PJ; Rohrback BG; Thiele E; Whalley B; Friedman D
Epilepsia; 2014 Jun; 55(6):791-802. PubMed ID: 24854329
[TBL] [Abstract][Full Text] [Related]
18. Use of cannabidiol in the treatment of epilepsy.
Mazurkiewicz-Bełdzińska M; Zawadzka M
Neurol Neurochir Pol; 2022; 56(1):14-20. PubMed ID: 35211946
[TBL] [Abstract][Full Text] [Related]
19. Outcomes from a Spanish Expanded Access Program on cannabidiol treatment in pediatric and adult patients with epilepsy.
Villanueva V; García-Ron A; Smeyers P; Arias E; Soto V; García-Peñas JJ; González-Alguacil E; Sayas D; Serrano-Castro P; Garces M; Hampel K; Tomás M; Lara J; de Toledo M; Barceló I; Aledo-Serrano A; Gil-Nagel A; Iacampo L; Falip M; Saiz-Diaz RA; Gómez-Ibañez A; Sopelana D; Sanchez-Larsen A; López-González FJ
Epilepsy Behav; 2022 Dec; 137(Pt A):108958. PubMed ID: 36327646
[TBL] [Abstract][Full Text] [Related]
20. Source of cannabinoids: what is available, what is used, and where does it come from?
Specchio N; Pietrafusa N; Cross HJ
Epileptic Disord; 2020 Jan; 22(S1):1-9. PubMed ID: 31941643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]